Dennis Ostwald, CEO of the WifOR Institute, and Sonja Haut, Head Impact Valuation at Novartis, take us on a deep dive into health from the perspective of its economic impact, how Novartis is implementing impact valuation, and what this approach could mean for the Biopharma sector.
